As of Oct 26
| -0.20 / -0.67%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 34.14, with a high estimate of 46.53 and a low estimate of 25.90. The median estimate represents a +15.37% increase from the last price of 29.59.
The current consensus among 33 polled investment analysts is to Hold stock in AstraZeneca. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.